Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

UBS Downgrades Advanced Neuromodulation

UBS Financial downgrades pain management device company Advanced Neuromodulation Systems (ANSI) to reduce from neutral.

Analyst Patrick Pace says he's concerned about an increasingly competitive environment in the chronic pain market and its effect on revenue growth.

Although Advanced Neuromodulation has a rechargeable battery product like Medtronic and Boston Scientific, he believes shares are at risk as Boston Scientific tries to gain a foothold in the marketplace.

While Pace continues to believe the main driver of incremental value for the company is the development of new products in the pipeline, he doesn't see an impact until 2008.

He says upside risk to reduce rating is acquisition of company, which the stock price already reflects potential. He keeps his $31 target.

blog comments powered by Disqus